Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Libtayo (cemiplimab-rwlc) for the Treatment of CSCC

Drug Name

Libtayo (cemiplimab-rwlc)

Developers

Regeneron and Sanofi Genzyme

Therapy Class

Monoclonal antibody

Product Description

Recombinant human immunoglobulin G4 (IgG4) monoclonal antibody

Current Indication

Metastatic cutaneous squamous cell carcinoma

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top